Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K3 | Q8IVH8 | 3/20 | 0.38 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 4/20 | 0.33 |
| ▸ | SIK1 | P57059 | 1/20 | 0.33 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | MET | P08581 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31435973 | 0.92 | CYP3A4 (0.35) | EIF2AK3HTR6METSCN9APIM1 | |
| SCHEMBL31436005 | 0.90 | MAP4K3 (0.37) | MAP4K3EIF2AK3PAK1SIK1SIK3 | |
| SCHEMBL30365155 | 0.86 | PTPN11 (0.40) | MAP4K3EIF2AK3PAK1SIK1SIK3 | |
| SCHEMBL31435977 | 0.83 | PTPN11 (0.39) | MAP4K3PAK1SIK1SIK3HTR6 | |
| SCHEMBL31435980 | 0.83 | MAP4K3 (0.38) | MAP4K3PAK1HTR6METALK | |
| SCHEMBL31435974 | 0.83 | ELANE (0.32) | MAP4K3PAK1MET | |
| SCHEMBL31436018 | 0.82 | CHRM3 (0.34) | HTR6METPIM1PIM2 | |
| SCHEMBL31435900 | 0.82 | MAP4K3 (0.41) | MAP4K3PAK1HTR6METALK | |
| SCHEMBL31435979 | 0.82 | PTPN11 (0.40) | MAP4K3HTR6PIM1PIM2 | |
| SCHEMBL31435920 | 0.78 | PTPN11 (0.41) | MAP4K3HTR6PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2025-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | TYRO3, TH, TYR | MAP4K3 262/4885EIF2AK3 3847/4885PAK1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.